Lantheus Holdings, Inc. (LNTH)

Market Cap	6.53B +16.1%
Revenue (ttm)	1.55B +0.6%
Net Income	279.03M +9.7%
EPS	4.16 +17.8%
Shares Out	65.11M
PE Ratio	24.09
Forward PE	18.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,081,769
Open	96.46
Previous Close	96.30
Day's Range	95.00 - 101.66
52-Week Range	47.25 - 103.89
Beta	-0.04
Analysts	Strong Buy
Price Target	105.23 (+4.97%)
Earnings Date	May 7, 2026

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 1,193
• Stock Exchange: NASDAQ
• Ticker Symbol: LNTH
• Website: https://www.lantheus.com

Financial Performance

In 2025, Lantheus Holdings's revenue was $1.54 billion, an increase of 0.50% compared to the previous year's $1.53 billion. Earnings were $233.56 million, a decrease of -25.25%.

Analyst Summary

According to 13 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price target is $105.23, which is an increase of 4.97% from the latest price.

Price Target

$105.23

(4.97% upside)

Analyst Consensus: Strong Buy